Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2019-11-12 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the third quarter ended September 30, 2019. However, the actual financial results are not included in the text; instead, it references a press release (Exhibit 99.1) that contains the financial information. The document length is 3087 characters, which is relatively short and consistent with a filing that announces or furnishes a press release rather than containing the full financial report itself. According to the "Menu vs Meal" rule, since this document is short and references an attached press release for the financial results, it should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER). The document is not a full earnings release but a regulatory filing that includes a press release as an exhibit. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-11-12 English
Regulatory Filings 2019
Regulatory Filings
2019-10-01 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes an amendment to the company's Certificate of Incorporation to increase authorized shares, which is a capital structure change. The document includes the Certificate of Amendment as an exhibit and is dated September 30, 2019. The length is 4283 characters, which is relatively short and typical for an 8-K filing. The document is not a full financial report but an announcement of a corporate action related to capital changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-09-30 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, specifically about the timing of the effectiveness of a filing. The document does not contain financial statements, management discussion, audit information, or any detailed report content. It is a regulatory communication related to a capital markets filing but does not itself constitute a capital/financing update report or a registration statement. Given the nature of the document as a formal regulatory correspondence and the absence of substantive financial or operational data, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2019-09-26 English
DEF 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'DEF 14C' and is an Information Statement pursuant to Section 14(c) of the Securities Exchange Act of 1934. It details a stockholder action by written consent to approve an amendment increasing the authorized shares of common stock. The document includes detailed information about the stockholder vote, ownership percentages, and legal references to Delaware General Corporation Law and SEC rules. It is not a proxy solicitation (explicitly states no proxy is requested), nor is it a voting results announcement. It is an information statement provided to shareholders about a corporate action taken by written consent. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes or inform about corporate actions. The document is substantive and not a brief announcement or a report publication notice. Therefore, the correct classification is PSI with high confidence.
2019-09-10 English
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, fiscal period dates, or document titles that would allow identification of a specific filing type. The text does not include any indication of being a report, announcement, certification, or any other recognizable financial or corporate filing document. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as the default category for filings that do not fit into other specific categories.
2019-09-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.